DocumentsDate added
Original article
C. Sridhar1*,C. Anuradha2,C. Krithika3,Ramachandran Sudarshan4
1 Department of Medicine, Government Medical College and Hospital, Omandurar Government estate, Chennai, India
2 Department of Anaesthesiology, Madras Medical College, Chennai, India
3 Department of Oral medicine and radiology, Thai Moogambigai Dental College and Hospital, Chennai, India
4 Department Oral Medicine and radiology, Ultra Best Dental College and Hospital, Madurai, Tamil Nadu, India
Address reprint requests to:
*Dr. C. Sridhar, MD
Professor of Medicine, Government Medical College, Omandurar Government estate, Chennai
Article citation: C. Sridhar, C. Anuradha,C. Krithika, R. Sudarshan. Evaluation of habit patterns and clinical findings of oral submucous fibrosis in South Indian population. J Pharm Biomed Sci 2016;06(07):425–432. Available at www.jpbms.info
ABSTRACT
Objective To evaluate the habit patterns and clinical features of oral submucous fibrosis.
Materials and Methods A hospital-based cross sectional study was conducted in a sample of 75 subjects with clinically diagnosed oral submucous fibrosis. Prior to the treatment, a detailed habit history was elicited. Clinical symptoms and signs were recorded. Mouth opening, cheek flexibility and tongue protrusion were also recorded.
Results 93.33% had the habit of using processed areca nut products like Gutkha (54.66%), Mawa (20%). The burning sensation was the most common symptom seen in 82% of cases, followed by restricted mouth opening. Blanching and palpable fibrous bands were present in all cases. The mean mouth opening of the sample was 32.73 (±9.10) mm, cheek flexibility was 6.48 (±3.06) mm, and tongue protrusion was 43.92 (±10.24) mm.
Conclusion It is important to be familiar with the habit patterns and clinical features of oral submucous fibrosis to facilitate early diagnosis and prompt management to reduce oral cancer-related morbidity and mortality.
KEYWORDS oral submucosa fibrosis, oral cavity, areca nuts
REFERENCES
1.More CB, Gupta S, Joshi J, Varma SN. Classification system for oral submucous fibrosis. J Indian Acad Oral Med Radiol.2012;24(1):24–29.
2.Warnakulasuriya S, Johnson N, Van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36(10):575–580.
3.Pillai R, Balaram P, Reddiar KS. Pathogenesis of oral submucous fibrosis. Relationship to risk factors associated with oral cancer.Cancer, 1992;69(8);2011–2020.
4.Sudarshan R, Annigeri RG, Vijayabala GS, Krithiika C. Oral sub-mucous fibrosis: realities of etiology. Arch Oral Res.2012;8(2);153–160.
5.Sinor PN, Gupta PC, Murti PR, Bhonsle RB, Daftary DK, Mehta FS, et al. A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med. 1990;19(2):94–98.
6.Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis – a collagen metabolic disorder. J Oral Pathol Med. 2005;34(6):321–328.
7.Fedorowicz Z, Chan Shih-Yen E, Dorri M, Nasser M, Newton T, Shi L. Interventions for the management of oral submucous fibrosis. Cochrane Database Syst Rev. 2008;4:CD007156.doi:10.1002/14651858.CD007156.pub2.
8.Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S. Oral submucous fibrosis: Review on aetiology and pathogenesis. Oral Oncol. 2006;42(6):561–568.
9.Aziz SR. Oral submucous fibrosis: case report and review of diagnosis and treatment. J Oral Maxillofacial Surg. 2008;66(11):2386–2389.
10.Kerr A, Warnakulasuriya S, Mighell A, Dietrich T, Nasser M, Rimal J, et al. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral Dis.2011;17(s1):42–57.
11.Reddy V, Wanjari P, Banda NR, Reddy P. Oral submucous fibrosis: Correlation of clinical grading to various habit factors. Int J Dental Clin. 2011;3(1):21–24.
12.Gupta P, Sinor P, Bhonsle R, Pawar V, Mehta H. Oral submucous fibrosis in India: a new epidemic? Natl Med J India.1998;11(3):113–116.
13.Kumar K, Saraswathi T, Ranganathan K, Devi U, Elizabeth J.Oral submucous fibrosis: A clinico-histopathological study in Chennai. Ind J Dental Res. 2007;18(3):106.
14.Gupta VK, Malhotra S, Patil R, Tripathi A. Oral submucous fibrosis at pediatric age, now time to think: Series of two cases. Ind J Med Paediat Oncol. 2013;34(2):107.
15.Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology. 2003;8(4):419–431.
16.Gupta PC, Ray CS. Tobacco and youth in the South East Asian region. Ind J Cancer. 2002;39(1):5–34.
17.Ahmad MS, Ali S, Ali A, Chaubey K. Epidemiological and etiological study of oral submucous fibrosis among gutkha chewers of Patna, Bihar, India. J Ind Soc Pedodont Prevent Dentist. 2006;24(2):84.
18.Babu S, Venkataramana Bhat R, Uday Kumar P, Sesikaran B, Visweswara Rao K, Aruna P, et al. A comparative clinico-pathological study of oral submucous fibrosis in habitual chewers of pan masala and betelquid. Clin Toxicol. 1996;34(3):317–322.
19.Shah N, Sharma P. Role of chewing and smoking habits in the etiology of oral submucous fibrosis (OSF): a case‐control study. J Oral Pathol Med. 1998;27(10):475–479.
20.Lee C, Ko Y, Huang H, Chao Y, Tsai C, Shieh T, et al. The precancer risk of betel quid chewing, tobacco use and alcohol consumption in oral leukoplakia and oral submucous fibrosis in southern Taiwan. British J Cancer. 2003;88(3):366–372.
21.Ariyawardana A, Athukorala A, Arulanandam A. Effect of betel chewing, tobacco smoking and alcohol consumption on oral submucous fibrosis: a case–control study in Sri Lanka. J Oral Pathol Med. 2006;35(4):197–201.
22.Krishnamoorthy B, Khan M. Management of oral submucous fibrosis by two different drug regimens: A comparative study.Dental Res J. 2013;10(4):527.
23.Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2007;103(2):207–213.
24.Gupta S, Khanna S, Singh M, Singh P. Histological changes to palatal and paratubal muscles in oral submucous fibrosis. J Laryngol Otol. 2000;114(12):947–950.
25.Ali FM, Patil A, Patil K, Prasant M. Oral submucous fibrosis and its dermatological relation. Indian Dermatol Online J. 2014;5(3):260.
26.Joseph AP, Rajendran R. Submucosa precedes lamina propria in initiating fibrosis in oral submucous fibrosis-evidence based on collagen histochemistry. J Oral Maxillofacial Pathol. 2010;1(1):3–7.
27.Zain RB, Ikeda N, Gupta PC, Warnakulasuriya S, Wyk CW, Shrestha P, et al. Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25‐27, 1996. J Oral Pathol Med. 1999;28(1):1–4.
28.Pindborg J, Mehta F, Gupta P, Daftary D. Prevalence of oral submucous fibrosis among 50,915 Indian villagers. British journal of cancer. 1968;22(4):646.
29.Khanna J, Andrade N. Oral submucous fibrosis: a new concept in surgical management: report of 100 cases. Int J Oral Maxillofacial Surg. 1995;24(6):433–439.
30.Cox S, Walker, D. Oral submucous fibrosis. A review. Australian Dent J. 1996;41(5):294–299.
31.Wahi P, Kapur V, Luthra UK, Srivastava M. Submucous fibrosis of the oral cavity. 1. Clinical features. Bulletin of the World Health Organization. 1996;35(5):789.
32.Zawawi KH, Al-Badawi EA, Lobo SL, Melis M, Mehta NR. An index for the measurement of normal maximum mouth opening. J Canadian Dental Association, 2003;69(11):737–741.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflicts of interest: The authors have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Giorgio Maria Paul Graziano1, Giovanni Castelli2, Antonino Graziano3*
1 University of Catania Medical School Italy
2 Prof Contract University of Catania Medical School Italy
3 Aggregate Professor University of Catania, Medical School Italy Azienda, Policlinico, Department of Sciences Medical Surgery and advanced technologies “G Ingrassia”
Address reprint requests to:
*Prof Antonino Graziano, Department of Sciences Medical Surgery and advanced technologies “G Ingrassia” via S Sofia 86-Cap 95125 Catania Italy
Article citation: Graziano GMP, Castelli G, Graziano A. Vascular thoracic fibrous adipose tissue (new disease). J Pharm Biomed Sci 2016;06(07):419–424. Available at www.jpbms.info
ABSTRACT
Introduction The primary tumors of the chest wall are rare, about 2% of all cancers, and 50% are derived from soft tissue neoplasms, benign or malignant that arise at the level of the chest wall representing 2% of all cancers; the study reports a recent observation of primitive thoracic neoplasia, and discusses the diagnosis and treatment of cancer.
Materials and Methods Paz 49 sex male has come to our attention in February 2016 at The Second Surgical Clinic of the University of Catania. The clinical history of the patient showed the presence in the dorsal thorax Ds, the formation presents a cranium caudal extension of about 190 mm, a lateral-lateral diameter of about 120 mm and an anteroposterior diameter of about 50 mm displaces posteriorly and the trapezius the latissimus dorsi and contracted close relations of contiguity with paraspinal muscles. It presents heterogeneous signal in T1 and T2.
Results The specifications with the different methods of imaging the face of a patient with expansive lesion that presented palpable mass in rapid growth (2), has been that of the identification of the lesion, with a spatial evaluation, typing, directing toward a diagnostic orientation of probable kindness.
Discussion The computed tomography (CT) allows in most cases the differential diagnosis of a neoplasm of the chest wall and defines its characteristics, the origin (in the case of the wall intrusive tumors by contiguity), the location, and the relationships with surrounding structures (Fig. 1). It also allows a more accurate staging. The choice of surgical strategy suffers first objective to be achieved: the radical or palliation.
Conclusion The described chest wall neoplasm is an example of how the pathologic classification is rapidly evolving thanks to new diagnostic techniques the therapeutic choices of benign primary lesions that generally occur as formations in sharp and regular margins, with a growth pattern of expansive and slow type. In the light of the latest findings in relation to the characteristics of important seat adipose tissue of adult stem cells, which are highly multidifferent, it is possible that if the cells are subjected to various types of stimuli can hypothesize and verify the activation to malignancy in time. The initiated research is that through an analysis of the lesion and on misuse formations mainly fat is it possible to get a review of the criteria in benign adipose tissue tumors.
KEYWORDS chest wall tumor treatment, vascular thoracic fibrous, cancer
REFERENCES
1.De Alava E, Pardo J. Ewing tumor: tumor biology and clinical applications. Int J Surg Pathol. 2001;9:717.
2.Sandberg AA. Cytogenetics and molecular genetics of bone and soft-tissue tumors. Am J Med Genet. 2002;115:189–193.
3.Rosai J. Special techniques in surgical pathology. In: Rosai J. (Ed) Rosai and Ackerman’s Surgical Pathology. 9th Ed. Edinbrough, CV Mosby. 2004:37–91.
4.Askin FB, Rosai J, Sibley RK, Dehner LP, McAllister WH. Malignant small cell tomor of the thoracopulmonary region in childhood. A distinctive clinicopathologic entity of uncertain histogenesis.Cancer. 1979;43:2438–2451.
5.A Colombo et al attività cellule staminali bollettino soc medico Pavia vol 214, 2011.
6.Kim SY, Lee JS, Ro JY, Gay ML, Hong WK, Hittleman WN. Interphase cytogenetics in paraffin sections of lung tumors by non-isotopic in situ hybridization. Mapping genotype/ fenotype heterogeneity. Am J Pathol. 1993;142:307–317.
7.Vassilopoulos PP, Voros DN, Kelessis NG, Apostolikas NG. Unusual spread of liposarcoma. Anticancer Res. 2001;21: 1419–1422.
8.Virkus WW, Mollabashy A, Reith JD, Zlotecki RA, Berrey BH,Scarborough MT. Preoperative radiotherapy in the treatment of soft tissue sarcomas. Clin Orthop Relat Res. 2002;397:177–189.
9.Layfield LJ ed. Lipomatous Neoplasms. In Cytopathology of Bone and Soft Tissue Tumors. Oxford, 2002, Oxford University Press, pp 71–88.
10.Christopher DM, Unni KK, Mertens F. WHO classification of tumors. Pathology and genetics: tumors of soft tissue and bone.Lyon, France, 2002, IARC Press, 35–46.
11.Wolman SR. Fluorescence in situ hybridisation. A new tool for the pathologist. Hum Pathol. 1994;25:586–590.
12.Grady WW, Cheng L, Lewin KJ. Application of in situ DNA hybridization technology to diagnostic surgical pathology. Pathol Annu. 1987;22:151–175.
13.Houldsworth J, Chaganti RS. Comparative genomic hybridization. An overview. Am J Pathol. 1994;145:1253–1260.
14.Naber SP, Smith LL Jr, Wolfe HJ. Role of frozen tissue bank in molecular pathology. Diagn Mol Pathol. 1992;1:73–79.
15.Mies C, Houldsworth J, Chaganti RS. Extraction of DNA from paraffin blocks for Southern blot analysis. Am J Surg Pathol. 1991;15:169–174.
16.Erlich HA, Gelfand D, Sninsky JJ. Recent advances in the polymerase chain reaction. Science. 1991;252:1643–1651.
17.Heller MJ. DNA microarray technology: devices, systems, and applications. Annu Rev Biomed Eng. 2002;4:129–153.
18.Bertucci F, Viens P, Tagett R, Nguyen C, Houlgatte R, Birnbaum D. DNA arrays in clinical oncology: promises and challenges. Lab Invest. 2003;83:305–316.
19.Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors– a sub group of small-roundcell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331:294–299.
20.Kumar S, Pack S, Kumar D, Walker R, Quezado M, Zhuang Z, et al. Detection of EWS-FLI-1 fusion in Ewing’s sarcoma/ peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue. Hum Pathol. 1999;30:324–330.
21.Kumar S, Pelman E, Haris CA, Raffeld M, Tsokos M. Myogenin is a specific marker for rhabdomyosarcomas: an immunohistochemical study on paraffin-embedded tissues. Mod Pathol. 2001;13:988–993.
22.Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicatorsin alveolar rhabdomyosarcoma: a report from the chidren’s oncology group. J Clin Oncol. 2002;20:2672–2679.
23.Isihda M, Miyamoto M, Naitoh S, Tatsuda D, Hasegawa T, Nemoto T, et al. The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. Mol Cell Biol. 2007;27:1348–1355.
24.Patricia M. McCormack, “Surgical management of chest wall tumors”, In: Arther E. Baue, Alexander S. Geha, Graeme L. Hammond, Hillel Lacks, Keith S. Naunhiem, Glenn’s Thoracic and Cardiovascular Surgery, 6th edition, Appleton and Lange.1990;593–607.
25.Kamal A, Mansour MD, Vinod H, Thourani MD, Albert Losken MD, Jamis G, et al. Chest wall resection and reconstruction: A 25 year experience. Ann Thorac Surg. 2002;73(1):720–726.
26.Graeber GM, Langenfeld J. Chest wall resection and reconstruction,In: Franco KL, Putman JR, eds. Advanced therapy in thoracic surgery. London: BC Decker, 1998;175–185.
27.Cavallaro A, Giorgio MPG, Cavallaro M, Graziano A. The neuroendocrine cancer personal comments and operational remarks. J Surg Surg Res. 2015;1:53–58.
28.Graeber GM. Chest wall resection and reconstruction. Semin Thorac Cardiovasc Surg. 1999;11(3):251–263.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflicts of interest: The authors have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Gao Ruitao1,Ou Yang1,Liu Wu1,Wang Gaofang1,Li Sha2,Jiang Jie1,3*
1 Institute of New Drug Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou 510632, China
3 Dongguan Institute of Jinan University, Dongguan 523808, China
Address reprint requests to:
*Jiang Jie, Institute of New Drug Research,College of Pharmacy, Jinan University, Guangzhou 510632, Dongguan Institute of Jinan University, Dongguan 523808, China
Article citation: Ruitao G, Yang O, Wu L,Gaofang W, Sha L, Jie J. Influence of ortho group introduction on the alkylation of phenolic hydroxyl of apocynin. J Pharm Biomed Sci 2016;06(07):414–418.
ABSTRACT
Apocynin was widely studied in inflammation and oxidative stress related diseases and showed effectiveness. Structure-activity relationship study was carried out and intended
to figure out new lead compounds of better efficacy. In the structure-activity relationship study of apocynin, different ortho group introduction was found to obviously affect the alkylation of phenolic hydroxyl. In this work, different ortho substituents of apocynin phenolic hydroxyl were designed and synthesized to further discuss their influence on the reaction activity of the phenolic hydroxyl group. When compared with the introduction of electron withdrawing group, aldehyde group (–CHO), introduction of electron donating group, amine group (–NH2), at the ortho position improved the reactivity of phenolic hydroxyl. It enabled the alkylation of phenolic hydroxyl easily occurring under a mild condition with a yield increase at least 26%, thus facilitated the modification of apocynin in further steps.
KEYWORDS apocynin, alkylation, phenolic hydroxyl, ortho substituent
REFERENCES
1.Yu J, Weiwer M, Linhardt RJ, Dordick JS. The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol. 2008;6(3):204–217.
2.Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol. 1994;11(1):95–102.
3.Pearse DB, Dodd JM. Ischemia-reperfusion lung injury is prevented by apocynin, a novel inhibitor of leukocyte NADPH oxidase. Chest. 1999;116(1 Suppl):55S–56S.
4.Ximenes VF, Brunetti IL, Fonseca LM. Apocynin and related methoxy-catechols as inhibitors of neutrophil-NADPH oxidase in LPS-activated whole blood. Res. J Biol Sci. 2007;2(3):360–364.
5.Abdelmageed ME, El-Awady MS, Suddek GM. Apocynin ameliorates endotoxin-induced acute lung injury in rats. Int Immunopharmacol.2016;30:163–170.
6.Pandey A, Kour K, Bani S, Suri KA, Satti NK, Sharma P, et al.Amelioration of adjuvant induced arthritis by apocynin. Phytother Res. 2009;23(10):1462–1468.
7.Peters EA, Hiltermann JT, Stolk J. Effect of apocynin on ozone-induced airway hyperresponsiveness to methacholine in asthmatics.Free Radic Biol Med. 2001;31(11):1442–1447.
8.Lu X, Wan S, Jiang J, Jiang X, Yang W, Yu P, et al. Synthesis and biological evaluations of novel apocynin analogues. Eur J Med Chem. 2011;46(7):2691–2698.
9.Xu L, Li Y, Wan S, Wang Y, Yu P. Protective effects of apocynin nitrone on acute lung injury induced by lipopolysaccharide in rats. Int Immunopharmcol. 2014;20:377–382.
10.Kulinkovich OG. Carbine methods for the introduction of acyl and acylmethyl groups into organic molecules. Russ Chem Rev.1989;58(8):711–719.
11.Neumann R, Sasson Y. Increased para selectivity in the Reimer-Tiemann reaction by use of polyethylene glycol as complexing agent. Synthesis.1986;(7):569–570.
12.Thoer A, Denis G, Delmas M, Gaset A. The Reimer-Tiemann reaction in slightly hydrated solid-liquid medium: a new method for the synthesis of formyl and diformyl phenols. Synthetic Communications. 1988;18(16–17):2095–2101.
13.Fu S, Zhan H, Yu H. Synthesis and characterization of N-hydroxybenzenamine and its N-acylation. J South China Univ Technolog (Nat Sci). 2000;28(5):59–63.
14.Sheng M, Yang B, Jian K, Ding Y, Zhang Z, Geng L. The research progress in the reduction of aromatic nitro compounds to the arylhydroxylamines. Agrochemicals. 2011;50(4):235–238, 252.
15.Anil Kumar NV, Rangappa KS. Synthesis and characterization of thymidine adducts of arylamines. Synthetic Commun. 2003;33(2):259–264.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: This research was supported by the National Natural Science Funds of China (81441128) and the National Science and Technology Support Project of the Ministry of Science and Technology of China (2013BAH08F04) to Jiang Jie..
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Samia MohamedAli Elamien1*,Omer Balla Ibrahim1,Selma Ali Albashir1
1 Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Sudan
Address reprint requests to:
*Samia MohamedAli Elamien,
Department of Chemical Pathology,Faculty of Medical Laboratory Sciences, Al Khartoum University, Sudan
Article citation: Elamien SM, Ibrahim OB, Albashir SA. The effect of pulmomary tuberculosis infection on some biochemical levels on liver and kidney tests at abu-anja hospital, sudan. J Pharm Biomed Sci 2016;06(07):410–413.
ABSTRACT
Background Pulmonary tuberculosis (TB) is associated with increased mortality and morbidity. Its exact aetiology has not been defined although several evidence indicate that various elements might play an important role in pulmonary tuberculosis changes in intracellular liver function, and renal function concentrations seem to be involved in the pathogenesis of pulmonary tuberculosis.
Objective The study was conducted to find out the role of pulmonary tuberculosis in liver and kidney impairments in newly diagnosed adult with pulmonary tuberculosis.
Methods The study group was composed of 50 newly adult diagnostic pulmonary tuberculosis(9 females and 41 males) while the group was 50 healthy individual (13 females and 37 males) controls analysed for liver function tests and renal function test by automated chemistry analysers (mind ray chemistry analyser Bs-200.
Results Both the serum liver function and renal function levels were significantly different in the pulmonary tuberculosis group as compared with the normal group.
Conclusion It can be concluded that a biochemical abnormality of liver and kidney level tests can play a significant role in the pathogenesis of pulmonary tuberculosis.
KEYWORDS pulmonary tuberculosis, liver, kidney, Abu, Anja.
REFERENCES
1.WHO Health Organization, GLOBAL Tuberculosis Control; Report 2010 in GENEUA 2010.
2.World Health organization WHO’s Global Tuberculosis Report 29 Act 2015, p. 2–4.
3.Gertz MA, Kyle RA. Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine (Baltimore). 1991;70:246–56.
4.Dixit R, Gupta R, Dave L, Prasad N, Sharma S. Clinical profile of patients having pulmonary tuberculosis and renal amyloidosis.Lung India. 2009;26(2):41–45.
5.Morris CD, Bird AR, Nell H. The hematological and biochemical changes in severe pulmonary tuberculosis. Q J Med. 1989;73(3):1151–1159.
6.WHO: GLOBAL Tuberculosis Control: Epidemiology, Strategy, Financing. 2009: pp. 7–46.
7.Mohammed OA, Muhammad HG. Alshammery College of Medicine University of Babylon, Hillah, Iraq. Med J Babylon. 2011;8(4).
8.Karyadi E, West CE, Schultink W, Nelwan RH, Gross R, Amin Z, et al. A double blind, placebo-controlled study of vitamin A and Zinc supplementation in persons with tuberculosis in Indonesia: effect on clinical response and nutritional status. Am J Clin Nutr. 2002;75:720–727.
9.Klote MM, Agodoa LY, Abbott KC. Risk factors for Mycobacterium tuberculosis in US chronic dialysis patients. Nephrol Dial Transplant. 2006;21(11):3287–92.
10.Conte G, Iavarone M, Santorelli V, De Nicola L. Acute renal failure of unknown origin. Don’t forget renal tuberculosis. Nephrol Dial Transplant. 1997;1260–1261.
11.Onwuliri VA. Total bilirubin, albumin, electrolytes and anion gap in HIV positive patient in Nigeria. J Med Sci. 2004;4(3):214–220.
12.Maity SG. Hepatobiliary tuberculosis–Therapeutic challenge, medicine up date 2005, p. 485-487.
13.Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme condition in Singapore. Int J Tuberc Lung Dis. 2002;6:699–705.
14.Burits C, Ashwood E, David B. Tietiz Text Book of Clinical Chemistry. 4th Edition. (1999) W.B, Saunders Comp. U.S.A.
15.Szeto YT, Kwok TC, Benzie IF. Effects of a long-term vegetarian diet on biomarkers of antioxidant status and cardiovascular disease risk. Nutrition. 2004;20(10):863–6.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.